An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer

Inclusion Criteria: - Histologically confirmed cancer of the colon or rectum with documented metastasis - Measurable disease per RECIST v. 1.1 - Not candidates for curative surgery or curative radiation - Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin - Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab - Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method - Tumor confirmed to harbor a known RAS mutation per a standard local testing method - ECOG performance status of 0 or 1 - Patients must have adequate hematological, renal, and hepatic function - Female patients of childbearing potential must have a negative pregnancy test - Life expectancy of at least 6 months Exclusion Criteria: - Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study treatment - Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment - Prior treatment with irinotecan - Symptomatic brain metastases - Active autoimmune disease - Receiving immunosuppressive or myelosuppressive medications - Active, uncontrolled infections - Known HIV infection or active hepatitis B or C that requires anti-viral treatment - History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ - History of allergy or known hypersensitivity to any of the study drugs, study drug classes, - Uncontrolled or severe cardiac disease - Received any vaccine within 28 days prior to first study treatment